Abstract:BACKGROUND: The correlation between gestational hypertension-preeclampsia (GH-PE) and placenta previa (PP) is controversial. Specifically, it is unknown whether placenta previa has any effect on the various types of preeclampsia (PE), and the role PP with concurrent placenta accreta (PA) play in the occurrence of GH-PE are not well understood.OBJECTIVE: The aim of this study was to identify the effects of PP on GH, mild and severe preeclampsia (MPE and SPE), and early- and late-onset preeclampsia (EPE and LPE). Another aim of the study was to determine if concurrent PA impacts the relationship between PP and GH-PE.METHODS: A retrospective single-center study of 1,058 patients having singleton pregnancies with PP was performed, and 2,116 pregnant women were randomly included as controls. These cases were collected from a tertiary hospital and met the inclusion criteria for the study. Clinical information, including PP and the gestational age at the onset of GH-PE were collected. Binary and multiple logistic regression analyses were conducted after the confounding variables were controlled to assess the effects of PP on different types of GH-PE.RESULTS: There were 155 patients with GH-PE in the two groups. The incidences of GH-PE in the PP group and the control group were 2.5% (26/1058) and 6.1% (129/2116), respectively (P = 0.000). Binary and multiple regression analyses were conducted after controlling for confounding variables. Compared to the control group, in the PP group, the risk of GH-PE was reduced significantly by 78% (AOR: 0.216; 95% CI: 0.135-0.345); the risks of GH and PE were reduced by 55% (AOR: 0.451; 95% CI: 0.233-0.873) and 86% (AOR: 0.141; 95% CI: 0.073-0.271), respectively; the risks of MPE and SPE were reduced by 73% (AOR: 0.269; 95% CI: 0.087-0828) and 88% (AOR: 0.123; 95% CI: 0.055-0.279), respectively; and the risks of EPE and LPE were reduced by 95% (AOR: 0.047; 95% CI: 0.012-0.190) and 67% (AOR: 0.330; 95% CI: 0.153-0.715), respectively. The incidence of concurrent PA in women with PP was 5.86%; PP with PA did not significantly further reduce the incidence of GH-PE compared with PP without PA (1.64% vs. 2.51%, P>0.05). Binary logistic regression analyses were conducted after controlling for confounding variables, compared with the non-PP + GH-PE group, and the AOR of FGR in the non-PP + non-GH-PE group was 0.206 (0.124-0.342). Compared with the PP + GH-PE group, the AOR of FGR in the PP + non-GH-PE group was 0.430 (0.123-1.500).CONCLUSION: PP is not only associated with a significant reduction in the incidence of GH-PE, but also is associated with a reduction in incidence of various types of PE. Concurrent PA and PP do not show association with a reduction in incidence of GH-PE.

Clinical Features of Preeclampsia Preceded by Fetal Growth Restriction

Fetal Growth Restriction: Does an Integrated Maternal Hemodynamic-Placental Model Fit Better?

Pregnancy Outcome in Early versus Late Onset Preeclampsia

The Feto-Maternal Outcomes and Incidence of Early-and Late-Onset Preeclampsia

Fetal growth restriction as the initial finding of preeclampsia is a clinical predictor of maternal and neonatal prognoses: a single-center retrospective study

Clinical Characteristics and Pregnancy Outcomes of Preeclampsia Complicated with Fetal Growth Restriction

Preeclampsia, Fetal Growth Restriction, and 24-Month Neurodevelopment in Very Preterm Infants

Mode of delivery and neonatal outcomes with early preterm severe preeclampsia: does fetal growth restriction matter?

Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia

Comparing Maternal and Perinatal Outcomes in Pregnancies Complicated by Preeclampsia Superimposed Chronic Hypertension and Preeclampsia Alone

Severe early-onset PE with or without FGR in Chinese women

If Fetal Growth Restriction Happened in Severe Early - Onset Preeclampsia is a Measure of Severity of Disease.

[Clinical features and prognosis of early-onset preeclampsia].

Correlation of 24-h Urinary Protein Excretion, Serum Indicators, and Placental Growth Factor in Patients with Preeclampsia and their Adverse Outcome

Preeclampsia and timing of delivery: Disease severity, maternal and perinatal outcomes

Ri sk factors fo recurrent preeclampsia and i ts relation ot mta ernal and fo fspring outcome

[Clinical Delimitation and Expectant Management of Early Onset of Severe Pre-Eclampsia].

Expectant management of preeclampsia with severe features diagnosed at less than 24 weeks

Maternal and Perinatal Prognosis of Pregnancy with Chronic Hypertension and Analysis of Associated Factors

Analyzing clinical features and forecasting pregnancy outcomes of early-onset severe preeclampsia

Effect of Placenta Previa on Preeclampsia